Carregant...
Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme carries out A-to-I editing of RNA to prevent sensing of endo...
Guardat en:
| Publicat a: | Oncogene |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7796950/ https://ncbi.nlm.nih.gov/pubmed/33110236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01515-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|